Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
Register for the first-ever Pharmaceutical Multi-Channel Marketing Strategy Conference, an industry-specific meeting featuring top leaders and latest trends in the pharmaceutical space. The conference, hosted by Q1 Productions, will feature sessions and interactive panel discussions addressing top concerns within pharmaceutical marketing, including the most effective marketing techniques to increase e-prescribing, the impact of marketing and shifting healthcare models, and developing content for increasingly complex channels. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!